Neuropathic Pain Market Report 2026

The neuropathic pain market size has grown strongly in recent years. It will grow from $5.78 billion in 2025 to $6.2 billion in 2026 at a compound annual growth rate (CAGR) of 7.3%. The growth in the historic period can be attributed to rising prevalence of diabetes, early adoption of antidepressants and anticonvulsants, increased awareness of neuropathic pain conditions, development of opioid-based treatments, initial use of imaging for diagnosis.

The neuropathic pain market size is expected to see strong growth in the next few years. It will grow to $8.48 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to growing shift toward non-opioid therapies, rising demand for personalized pain management, expansion of complementary therapy usage, increasing investment in diagnostic innovations, development of advanced multimodal treatment solutions. Major trends in the forecast period include rising adoption of multimodal therapy approaches, increasing demand for non-opioid pain management, growing use of physical and psychological therapy integration, expansion of early diagnosis through imaging techniques, increasing focus on diabetic neuropathy treatment.

The growing prevalence of chronic pain is expected to drive the expansion of the neuropathic pain market in the coming years. Chronic pain is characterized by persistent discomfort lasting three months or longer, affecting a significant portion of the population and substantially reducing quality of life. The rise in chronic pain cases is largely attributed to aging populations, nerve injuries, and long-term conditions such as diabetes. Therapies for neuropathic pain play an important public health role by addressing nerve dysfunction, alleviating symptoms, and improving patients’ daily functioning. For example, in November 2024, data from the Centers for Disease Control and Prevention (CDC), a US-based national health protection agency, showed that 24.3% of adults experienced chronic pain and 8.5% experienced high-impact chronic pain in 2023, with women, American Indian and Alaska Native adults, and individuals aged 65 years and older reporting significantly higher rates. As a result, the increasing burden of chronic pain is driving growth in the neuropathic pain market.

Companies operating in the neuropathic pain market are increasingly adopting artificial intelligence-based technologies to enable advanced diagnostics, personalized treatment strategies, real-time patient monitoring, drug discovery, and data-driven insights that enhance pain management outcomes. For instance, in March 2023, Nevro Corp., a US-based medical device company, launched the Senza HFX iQ spinal cord stimulation (SCS) system, an AI-enabled solution designed to deliver customized pain relief. The system includes the HFX iQ implantable pulse generator, trial stimulator, charger, and a companion mobile application, and is intended for the treatment of non-surgical back pain and painful diabetic neuropathy. By leveraging an algorithm built on extensive patient data, the system adapts to individual patient responses and allows users to adjust therapy through a smartphone interface. Its digital ecosystem supports continuous data collection and future updates, representing a significant advancement in personalized SCS therapy.

In July 2023, Novartis AG, a Switzerland-based multinational pharmaceutical company, acquired DTx Pharma for an undisclosed amount. Through this acquisition, Novartis strengthened its neuroscience portfolio by gaining access to DTx Pharma’s small interfering RNA (siRNA) development platform, supporting the advancement of RNA-based therapies for neurological disorders. DTx Pharma is a US-based preclinical biotechnology company focused on developing innovative RNA therapies for neuropathic pain.

Major companies operating in the neuropathic pain market are Pfizer Inc., Johnson & Johnson Private Limited, Sanofi S.A., Bristol‑Myers Squibb Company, Abbott Laboratories, GlaxoSmithKline Plc, Medtronic Inc., Eli Lilly and Company, Teva Pharmaceutical Industries Ltd, Boston Scientific Corporation, Sun Pharmaceutical Industries Ltd., Mallinckrodt Pharmaceuticals, Grünenthal GmbH, Lupin Ltd., Nevro Corp., InvaGen Pharmaceuticals Inc, Centaur Pharmaceuticals Pvt Ltd., Stimwave LLC, Novartis AG, Astellas Pharma Inc., Vertex Pharmaceuticals Incorporated, Assertio Therapeutics Inc, NeuroMetrix Inc, OMRON Healthcare Co Ltd.

North America was the largest region in the neuropathic pain market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neuropathic pain market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the neuropathic pain market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs are affecting the neuropathic pain market by increasing the costs of pharmaceutical ingredients, diagnostic equipment, and imported pain management devices used in multimodal therapy. These tariffs particularly impact hospitals, clinics, and ambulatory surgical centers in regions reliant on imported medical supplies, including Asia-Pacific and parts of Europe. Treatment segments such as medications, physical therapy tools, and diagnostic imaging systems face higher procurement costs and extended delivery timelines. Despite the challenges, tariffs are encouraging domestic pharmaceutical production, supply chain diversification, and enhanced local manufacturing of pain therapy equipment.

The neuropathic pain market research report is one of a series of new reports that provides neuropathic pain market statistics, including neuropathic pain industry global market size, regional shares, competitors with a neuropathic pain market share, detailed neuropathic pain market segments, market trends and opportunities, and any further data you may need to thrive in the neuropathic pain industry. This neuropathic pain market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Neuropathic pain is a long-term pain condition resulting from damage or dysfunction within the nervous system and is characterized by sensations such as burning, tingling, shooting pain, or electric shock-like feelings. It can be difficult to manage and may arise from nerve injuries, diabetes, multiple sclerosis, nerve compression, neural degeneration, or disorders of the central nervous system.

The primary approaches to neuropathic pain treatment include medications and multimodal therapy. Medications involve the use of pharmaceutical agents to relieve symptoms or manage the condition, and certain drug classes, such as anticonvulsants, antidepressants, and opioids, are used to target nerve-related abnormalities and pathways, thereby reducing the intensity of neuropathic pain signals and providing relief. Neuropathic pain is diagnosed through imaging techniques, blood tests, and physical examinations and is associated with conditions such as diabetic neuropathy, spinal stenosis, chemotherapy-induced peripheral neuropathy, and others, with care provided by hospitals, clinics, home healthcare settings, ambulatory surgical centers, and other healthcare facilities.

The neuropathic pain market consists of revenues earned by entities by providing physical therapy services, acupuncture services and relaxation services. The market value includes the value of related goods sold by the service provider or included within the service offering. The neuropathic pain market also includes sales of anticonvulsants, antidepressants, opioids, topical creams and transcutaneous electrical nerve stimulation devices, which are used in providing neuropathic pain diagnosis and treatment. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.